Edition:
India

Neuralstem Inc (CUR.OQ)

CUR.OQ on NASDAQ Stock Exchange Capital Market

1.69USD
20 Sep 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$1.69
Open
$1.68
Day's High
$1.73
Day's Low
$1.60
Volume
14,407
Avg. Vol
17,290
52-wk High
$24.40
52-wk Low
$1.50

Latest Key Developments (Source: Significant Developments)

Neuralstem Q2 Loss Per Share $1.45
Wednesday, 14 Aug 2019 

Aug 14 (Reuters) - Neuralstem Inc ::NEURALSTEM REPORTS SECOND QUARTER 2019 FISCAL RESULTS.Q2 LOSS PER SHARE $1.45.NEURALSTEM - ANTICIPATES EXISTING CASH, CASH EQUIVALENTS TO FUND ITS OPERATIONS INTO Q3 2020.AT JUNE 30, 2019, CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE $2.3 MILLION.  Full Article

Intracoastal Capital LLC Reports 9.99% Passive Stake In Neuralstem Inc As Of July 30
Friday, 9 Aug 2019 

Aug 9 (Reuters) - Neuralstem Inc ::INTRACOASTAL CAPITAL LLC REPORTS 9.99% PASSIVE STAKE IN NEURALSTEM INC AS OF JULY 30 - SEC FILING.  Full Article

Neuralstem Announces Pricing Of $7.5 Mln Underwritten Public Offering
Friday, 26 Jul 2019 

July 25 (Reuters) - Neuralstem Inc ::NEURALSTEM ANNOUNCES PRICING OF $7.5 MILLION UNDERWRITTEN PUBLIC OFFERING.PRICES UNDERWRITTEN PUBLIC OFFERING OF 2.8 MILLION UNITS AT A PUBLIC OFFERING PRICE OF $2.70 PER UNIT FOR ABOUT $7.5 MILLION.  Full Article

Neuralstem Reports Q1 Loss Per Share $0.17
Wednesday, 15 May 2019 

May 14 (Reuters) - Neuralstem Inc ::NEURALSTEM REPORTS FIRST QUARTER 2019 FISCAL RESULTS.Q1 LOSS PER SHARE $0.17.AT MARCH 31, 2019, CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WAS $4.0 MILLION AS COMPARED TO $5.8 MILLION AT DECEMBER 31, 2018.EXPECTS ITS EXISTING CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TO FUND ITS OPERATIONS INTO Q3 OF 2019.  Full Article

Neuralstem Appoints Ken Carter As Executive Chairman Of The Board
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Neuralstem Inc ::NEURALSTEM APPOINTS KEN CARTER, PH.D., AS EXECUTIVE CHAIRMAN OF THE BOARD.KENNETH C. CARTER, PH.D., AS CO'S EXECUTIVE CHAIRMAN OF BOARD TO BE EFFECTIVE ON JANUARY 1, 2019.CARTER WILL REPLACE INTERIM CEO, JIM SCULLY, WHO WILL BE STEPPING DOWN.  Full Article

Neuralstem Q3 Loss Per Share $0.12
Thursday, 15 Nov 2018 

Neuralstem Inc ::NEURALSTEM REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE $0.12.  Full Article

Neuralstem Appoints Jim Scully As Interim CEO
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Neuralstem Inc ::NEURALSTEM APPOINTS JIM SCULLY AS INTERIM CHIEF EXECUTIVE OFFICER.NEURALSTEM - SCULLY WILL SUCCEEDS RICH DALY WHO SERVED AS PRESIDENT AND CEO OF COMPANY SINCE FEBRUARY 2016.  Full Article

Neuralstem says NSI-566 Stem Cell Therapy Confers Neurological Improvement In Spinal Cord Injury
Monday, 4 Jun 2018 

June 4 (Reuters) - Neuralstem Inc ::NEURALSTEM’S NSI-566 STEM CELL THERAPY CONFERS NEUROLOGICAL IMPROVEMENT IN SPINAL CORD INJURY PATIENTS WITH COMPLETE PARAPLEGIA.NEURALSTEM INC - ANALYSIS OF MOTOR AND SENSORY FUNCTION AND ELECTROPHYSIOLOGY RESULTS SHOWED IMPROVEMENT IN THREE OF FOUR PATIENTS.NEURALSTEM INC - ALL SUBJECTS TOLERATED PROCEDURE WELL, WITH NO SERIOUS ADVERSE EVENTS 18-27 MONTHS AFTER GRAFTING.  Full Article

Neuralstem Says At Dec. 31, 2017, Cash And Investments Was $11.7 Mln Compared To $20.2 Mln At Dec. 31, 2016
Monday, 2 Apr 2018 

April 2 (Reuters) - Neuralstem Inc ::NEURALSTEM REPORTS YEAR END 2017 FISCAL RESULTS AND BUSINESS UPDATE.AT DECEMBER 31, 2017, CASH AND INVESTMENTS WAS $11.7 MILLION AS COMPARED TO $20.2 MILLION AT DECEMBER 31, 2016.TERM INVESTMENTS TO FUND OPERATIONS INTO Q2 OF 2019.  Full Article

Neuralstem Q3 loss per share $0.01
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Neuralstem Inc :Neuralstem reports third quarter 2017 fiscal results and provides clinical and business update.Q3 loss per share $0.01.Neuralstem - ‍expect to provide detailed update on corporate strategy after post-phase 2 meeting with fda in h1 2018​.Neuralstem Inc - ‍ recent financing further extended co's cash runway to sufficiently support continued research on NSI-189 and to support operations​.Neuralstem Inc - ‍plans to meet with U.S. Food and Drug Administration in first half of 2018 to discuss clinical development path for NSI-189​.  Full Article